We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Chinese Devicemaker Health Line Gets 483 for CAPA, DHR Problems

Chinese Devicemaker Health Line Gets 483 for CAPA, DHR Problems

July 25, 2014

Health Line International, a Chinese devicemaker, received an FDA Form 483 for delaying effectiveness checks on CAPAs and other quality issues.

Eight out of the nine CAPAs reviewed by the FDA investigator only had effectiveness checks after the date of CAPA closure, according to the Jan. 9 form, which was recently released. The company’s CAPA procedures don’t discuss verification or validation of the activities, the form adds. They also don’t specify that data on quality problems should be shared with those responsible for product quality. Neither procedure discusses management review of such information.

The Form 483 followed a Jan. 6-9 inspection of Health Line’s Foshan, China, manufacturing facility.

The FDA investigator also looked at Health Line’s completed customer complaint forms and found they lacked addresses or records of replies. Complaints are classified by importance, but the records don’t specify who will evaluate the complaints for FDA reportability, the form says.

Additional observations relate to device history records. A review of six device history records showed that each included a copy of the product label but did not have a signed and dated record of examination and release. During the inspection, Health Line produced a copy of a form where it records label information. “However, I did not see that any record of this information was included in each DHR,” the investigator notes.

Meanwhile, the DHRs also failed to identify equipment used for measurements during final acceptance testing.

The investigator further found that Health Line’s nonconforming product procedure doesn’t require the documentation of rework and reevaluation activities in DHRs.

Health Line said it “immediately corrected” the observations and its corrective actions have been verified as effective. “The observations listed had no impact on product released to the field,” the company added.

Avoid a form 483. Prevent CAPA problems and write good reports by purchasing CAPA Documentation and Filing: How to Write Clear, Concise and Compliant Reports today!

Medical Devices Inspections and Audits

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 27Jan

    FDA’s Response to COVID-19: Fundamentals of Obtaining Emergency Use Authorizations

  • 09Feb

    Maintaining Your Risk-Based Cleaning and Disinfectant Programs: Best Practices During COVID-19

  • 10Feb

    FDA Under the Biden Administration: What’s to Come and What It Will Mean

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • Supreme Court Rejects Merck’s Appeal for $2.5 Billion Patent Verdict Reinstatement

  • FDA clears text

    FDA Clears SCC’s Transfusion-Management Software

  • CE mark

    MiRXES Earns CE Mark for COVID-19/Flu Test

  • KitePharma_Logo

    Kite Pharma’s Tecartus Gains UK Recommendation for Lymphoma

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing